var title_f11_30_11744="Telaprevir drug interactions";
var content_f11_30_11744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major drug interactions with protease inhibitors for treatment of chronic hepatitis C virus (genotype 1)*: Telaprevir",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Interacting class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management suggestions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Telaprevir undergoes CYP3A4 transformation and P-gp clearance. Co-administration of drugs that are strong inducers of CYP3A and/or P-gp are known to REDUCE telaprevir serum concentrations and should be avoided whenever possible.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticonvulsants",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Carbamazepine, fosphenytoin, oxcarbazepine, pentobarbital, phenobarbital, phenytoin, primidone",
"       </td>",
"       <td rowspan=\"3\">",
"        Reduced telaprevir serum concentrations, loss of telaprevir efficacy. Risk of HCV resistance and treatment failure.",
"       </td>",
"       <td rowspan=\"3\">",
"        Coadministration of these agents with telaprevir is contraindicated or not recommended according to the US prescribing information for telaprevir and/or interacting drug. Consider substituting non-interacting agents. Note that metabolic effects may persist for weeks following discontinuation of a strong inducer.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-infectives",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Nafcillin, rifampin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , rifabutin, rifapentine, certain HIV antiretrovirals",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Bosentan, dexamethasone, St. John's wort",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Telaprevir is a potent inhibitor of CYP3A4 and P-gp. Telaprevir may increase systemic exposure of a large number of drugs dependent on CYP3A and/or P-gp for clearance. The following is NOT a complete list of all potential interactions. See Lexi-Interact&trade; program included with UpToDate to check for additional telaprevir interactions.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Analgesic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Opioid",
"       </td>",
"       <td>",
"        Methadone",
"       </td>",
"       <td>",
"        &asymp;25 to 30 percent reduction in methadone serum concentration reported. Variable effects possible.",
"       </td>",
"       <td rowspan=\"2\">",
"        Monitor opioid effect. No specific dose adjustment recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buprenorphine, fentanyl, oxycodone",
"       </td>",
"       <td>",
"        Increased opioid concentration and effects possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Anti-infectives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antibiotics, macrolide",
"       </td>",
"       <td>",
"        Clarithromycin, erythromycin, telithromycin",
"       </td>",
"       <td>",
"        Increased serum concentrations of macrolide antibiotics. Risk of QTc prolongation and potential cardiotoxicity.",
"       </td>",
"       <td>",
"        Consider substituting a non-interacting antibiotic such as azithromycin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antifungals, triazole (systemic)",
"       </td>",
"       <td>",
"        Itraconazole, ketoconazole, posaconazole, voriconazole",
"       </td>",
"       <td>",
"        Serum concentrations of telaprevir and azole anti-fungals may be elevated. Risk of QTc prolongation and potential cardiotoxicity.",
"       </td>",
"       <td>",
"        If concurrent treatment is required, monitor for toxicity including QTc interval prolongation. Itraconazole and ketoconazole doses greater than 200 mg per day should be avoided.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-malarials",
"       </td>",
"       <td>",
"        Halofantrine, lumefantrine, quinine, quinidine",
"       </td>",
"       <td>",
"        Anti-malarial toxicity including cinchonism (quinine and quinidine), QTc prolongation, and risk of cardiotoxicity.",
"       </td>",
"       <td>",
"        Avoid co-administration of telaprevir with these anti-malarial drugs if possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV antiretrovirals",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Protease inhibitors, non-nucleoside reverse transcriptase inhibitors and tenofovir",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         Interactions between HIV antiretrovirals and telaprevir can result in viral resistance and therapeutic failure. For additional information, refer to topic Treatment of hepatitis C virus infection in the HIV-infected patient. These interactions are discussed separately. Early consultation with HIV/HCV infectious diseases specialist is recommended.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Antineoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Docetaxel, crizotinib",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , doxorubicin, gefitinib, imatinib, paclitaxel, pazopanib, sunitinib",
"       </td>",
"       <td>",
"        Increased serum concentration of antineoplastic and risk of toxicity.",
"       </td>",
"       <td>",
"        Closely monitor antineoplastic effects and adjust dose as needed. Concurrent treatment with crizotinib is contraindicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anticoagulants, orally active",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Apixaban",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , dabigatran, rivaroxaban",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , warfarin",
"       </td>",
"       <td>",
"        <p>",
"         Telaprevir has the potential to increase the risk of bleeding when used with apixaban, rivaroxaban or dabigatran.",
"        </p>",
"        Variable anticoagulant effects are associated with co-administration of telaprevir and warfarin.",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Concurrent treatment with rivaroxaban is contraindicated. Avoid dabigatran in any patient with renal insufficiency (CrCl &lt;50 mL/minute). According to the licensed prescribing information in some countries, avoidance of apixaban and dabigatran or dose reduction is recommended. See local prescribing information. If concomitant use is unavoidable, administer dabigatran at least two hours before telaprevir.",
"         <sup>",
"          &sect;",
"         </sup>",
"        </p>",
"        Warfarin may be preferred due to the availability of international normalized ratio (INR) monitoring. Close INR monitoring and warfarin dose adjustment is needed until INR is re-stabilized.",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antiarrhythmics",
"       </td>",
"       <td>",
"        Amiodarone, bepridil, digoxin, dronedarone, flecainide, lidocaine (systemic), propafenone, quinidine",
"       </td>",
"       <td>",
"        Elevated risk of cardiotoxicity, arrhythmias, and/or hypotension.",
"       </td>",
"       <td>",
"        Close monitoring of antiarrhythmic effects suggested, including serum concentrations, if available. Dose alteration of antiarrhythmic may be necessary. Initiate digoxin at lowest dose with titration according to digoxin serum concentrations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium channel blockers (CCBs)",
"       </td>",
"       <td>",
"        Amlodipine, bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, verapamil",
"       </td>",
"       <td>",
"        More pronounced blood pressure lowering and/or cardiac effects due to elevated CCB concentration.",
"       </td>",
"       <td>",
"        If concurrent use is necessary, monitor for exaggerated CCB effects and adjust CCB dose as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HMG-CoA reductase inhibitors (\"statins\")",
"       </td>",
"       <td>",
"        Atorvastatin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , lovastatin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , simvastatin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Increased statin concentrations and elevated risk of myopathy.",
"       </td>",
"       <td>",
"        Concurrent treatment with atorvastatin, lovastatin or simvastatin is contraindicated. Due to P-gp inhibition by telaprevir, pravastatin may interact but supporting data are not available. Fluvastatin is less likely to interact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Contraception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estrogen and progestogen combined hormonal contraception",
"       </td>",
"       <td>",
"        Ethinyl estradiol, mestranol, desogestrel, dienogest, drospirenone, ethynodiol diacetate, etonogestrel, levonorgestrel, medroxyprogesterone, norelgestromin, norethindrone, norgestimate, norgestrel",
"       </td>",
"       <td>",
"        Telaprevir may decrease the serum concentrations of ethinyl estradiol and alter the serum concentrations of progestogens causing failure of hormonal contraception.",
"       </td>",
"       <td>",
"        Women of child bearing potential should use two effective NON-hormonal methods of birth control. This is particularly important because ribavirin is teratogenic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antiemetic",
"       </td>",
"       <td>",
"        Aprepitant, fosaprepitant",
"       </td>",
"       <td>",
"        Increased antiemetic exposure.",
"       </td>",
"       <td>",
"        Monitor effect. No specific dose adjustment available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GI motility agent",
"       </td>",
"       <td>",
"        Cisapride",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , domperidone",
"       </td>",
"       <td>",
"        Increased QTc prolongation and risk of cardiotoxicity.",
"       </td>",
"       <td>",
"        Concurrent treatment with cisapride is contraindicated. Monitor domperidone effect.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Glucocorticoids and anti-gout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucocorticoids (systemic)",
"       </td>",
"       <td>",
"        Budesonide, dexamethasone, fludrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone",
"       </td>",
"       <td>",
"        Increased glucocorticoid concentrations. Dexamethasone may decrease telaprevir efficacy (see strong inducers, above).",
"       </td>",
"       <td>",
"        Monitor for increased glucocorticoid effects. No specific dose adjustment available. For dexamethasone recommendation, see strong inducers, above.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucocorticoids (inhaled or nasal)",
"       </td>",
"       <td>",
"        Budesonide, fluticasone",
"       </td>",
"       <td>",
"        Increased systemic exposure of inhaled/intranasal glucocorticoids.",
"       </td>",
"       <td>",
"        Avoid concurrent use with inhaled/intranasal budesonide or fluticasone. Beclomethasone and triamcinolone are less likely to interact. See interaction for long-acting beta agonist, salmeterol, below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-gout",
"       </td>",
"       <td>",
"        Colchicine",
"       </td>",
"       <td>",
"        Increased risk of colchicine toxicity including severe diarrhea, nausea and vomiting.",
"       </td>",
"       <td>",
"        For patients with normal renal/hepatic function the following colchicine dose reductions are suggested:",
"        <br/>",
"        <ul>",
"         <li>",
"          Acute gout: 0.6 mg once followed by 0.3 mg one hour later. Do not repeat before 72 hours.",
"         </li>",
"         <li>",
"          Gout prophylaxis: reduce dose by 50 percent; double interval",
"         </li>",
"         <li>",
"          Familial Mediterranean fever: maximum daily dose 0.6 mg",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Immunosuppressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Calcineurin inhibitors",
"        </p>",
"        mTOR kinase inhibitors",
"       </td>",
"       <td>",
"        Cyclosporine, tacrolimus, everolimus, sirolimus, temsirolimus",
"       </td>",
"       <td>",
"        Significantly elevated serum concentrations of calcineurin inhibitors and mTOR kinase inhibitors which could lead to renal failure, cardiotoxicity or other serious or life-threatening toxicity.",
"       </td>",
"       <td>",
"        Closely monitor immunosuppressant serum concentrations for signs of toxicity (eg, nephrotoxicity). Significant immunosuppressant dosage reductions may be needed. Numerous drugs taken by transplant recipients can interact with telaprevir. Drug therapy should be managed by transplant specialists with expertise in pharmacokinetic-based dose adjustment and management of high-risk drug interactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Pulmonary arterial hypertension and urologic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phosphodiesterase-5 inhibitors (PDE-5)",
"       </td>",
"       <td>",
"        Sildenafil",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , tadalafil",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , vardenafil",
"       </td>",
"       <td>",
"        Increased risk of hypotension, syncope, visual changes, and priapism.",
"       </td>",
"       <td>",
"        Concurrent use of telaprevir with PDE-5 inhibitors for treatment of pulmonary arterial hypertension is contraindicated. For treatment of erectile dysfunction, the following dose limits are suggested:",
"        <br/>",
"        <ul>",
"         <li>",
"          Limit sildenafil to single 25 mg dose per 48 hours",
"         </li>",
"         <li>",
"          Limit tadalafil to single 10 mg dose per 72 hours",
"         </li>",
"         <li>",
"          Limit vardenafil to single 2.5 mg dose per 72 hours",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha-1 antagonists",
"       </td>",
"       <td>",
"        Alfuzosin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , silodosin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , tamsulosin",
"       </td>",
"       <td>",
"        Increased risk of hypotension, syncope.",
"       </td>",
"       <td>",
"        Concurrent use of alpha-1 antagonists with telaprevir is contraindicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endothelin antagonist",
"       </td>",
"       <td>",
"        Bosentan",
"       </td>",
"       <td>",
"        Toxicities due to elevated bosentan exposure may include edema, hypotension, syncope, hematologic and hepatic abnormalities. In addition, bosentan may reduce telaprevir concentrations.",
"       </td>",
"       <td>",
"        Bosentan interacts with numerous drugs. Consider alternate non-interacting therapy. Also see strong CYP3A4 inducers, section \"other\" above.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Psychiatry, sedative and hypnotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Antidepressants",
"       </td>",
"       <td>",
"        Escitalopram",
"       </td>",
"       <td>",
"        Decreased escitalopram exposure reported in one study. Variable effects possible.",
"       </td>",
"       <td rowspan=\"2\">",
"        Dose alteration may be needed, but no specific guidance is available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buspirone, citalopram, desipramine, mirtazapine, nefazodone, trazodone, venlafaxine",
"       </td>",
"       <td>",
"        Increased antidepressant exposure possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        Alprazolam, clonazepam, diazepam, midazolam (oral",
"        <sup>",
"         &Delta;",
"        </sup>",
"        &gt; parenteral), triazolam",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Prolonged or excessive sedation.",
"       </td>",
"       <td>",
"        Use of oral midazolam or triazolam with telaprevir is contraindicated. Dose reduction of other benzodiazepines listed may be needed. Consider substituting a non-interacting benzodiazepine such as lorazepam, oxazepam, or temazepam.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypnotics",
"       </td>",
"       <td>",
"        Eszopiclone, zolpidem, zopiclone",
"       </td>",
"       <td>",
"        Increased hypnotic exposure possible. However, reduction in zolpidem serum concentration reported in one study.",
"       </td>",
"       <td>",
"        Dose alteration may be needed, but no specific guidance is available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroleptics (antipsychotics)",
"       </td>",
"       <td>",
"        Aripiprazole, haloperidol, iloperidone, pimozide",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , quetiapine",
"       </td>",
"       <td>",
"        QTc prolongation and elevated risk of cardiotoxicity.",
"       </td>",
"       <td>",
"        Concurrent use of pimozide is contraindicated. A 50 percent dose reduction with iloperidone is suggested. Dose reduction of other interacting neuroleptics may be needed, but no specific recommendation is available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-acting beta-agonist",
"       </td>",
"       <td>",
"        Salmeterol (inhaled)",
"       </td>",
"       <td>",
"        Increased systemic exposure to salmeterol. Increased risk of tachycardia and other adverse cardiovascular effects.",
"       </td>",
"       <td>",
"        Avoid inhaled salmeterol with telaprevir. Formoterol may be less likely to interact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ergot derivatives",
"       </td>",
"       <td>",
"        Dihydroergotamine",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , ergotamine",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , methylergonovine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Increased risk of ergotism characterized by peripheral vasospasm and ischemia.",
"       </td>",
"       <td rowspan=\"2\">",
"        Combined use of any agent shown in examples with telaprevir is contraindicated. Use non-interacting alternate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasopressin receptor antagonist",
"       </td>",
"       <td>",
"        Conivaptan",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Increased serum concentration of conivaptan.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CYP: cytochrome P450; P-gp: membrane P-glycoprotein multidrug resistance transporter; HCV: hepatitis C virus (genotype 1); CCB: calcium channel blocker; mTOR inhibitor: mammalian target of rapamycin inhibitor.",
"     <br/>",
"     * For information concerning specific interaction effects, see Lexi-Interact&trade; drug interactions application included with UpToDate.",
"     <br/>",
"     &Delta;",
"     <strong>",
"      Co-administration of telaprevir with these agents is contraindicated or not recommended according to the US prescribing information for telaprevir and/or the interacting drug.",
"     </strong>",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Treatment of HCV in HIV infected patient is discussed elsewhere. For additional information, refer to topic Treatment of hepatitis C virus infection in the HIV-infected patient.",
"     <br/>",
"     &sect; For additional information on interactions of novel oral anticoagulant interactions, refer to topic Anticoagulants other than heparin and warfarin.",
"     <br/>",
"     &yen; In a case report, a 1.5 times increase in chronic warfarin dose requirement followed a brief initial period of INR elevation when triple therapy, including telaprevir, was started in a patient on a stable warfarin regimen.",
"     <sup>",
"      [3]",
"     </sup>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Incivek&trade; (telaprevir) US prescribing information, available at: file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed0e4f33-cf21-4fe3-918d-1d5b3a23eee4.",
"      </li>",
"      <li>",
"       Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"      </li>",
"      <li>",
"       Gatti DC, Cha A. Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection. Am J Health-Syst Pharm. 2012; 69:2062-5.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11744=[""].join("\n");
var outline_f11_30_11744=null;
var title_f11_30_11745="Erythroderma in Sezary syndrome";
var content_f11_30_11745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythroderma in S&eacute;zary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 600px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythroderma, defined as erythema covering at least 80 percent of body surface area, is present in all patients with S&eacute;zary syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Non-Hodgkin Lymphomas, 2nd ed, Armitage JO, Mauch PM, Harris NL, et al. (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11745=[""].join("\n");
var outline_f11_30_11745=null;
var title_f11_30_11746="Pemphigoid vulva";
var content_f11_30_11746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11746=[""].join("\n");
var outline_f11_30_11746=null;
var title_f11_30_11747="Dyshidrotic eczema severe 2";
var content_f11_30_11747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Severe dyshidrotic eczema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11747=[""].join("\n");
var outline_f11_30_11747=null;
var title_f11_30_11748="Bypass revision for brachiocephalic fistula steal";
var content_f11_30_11748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Bypass revision for brachiocephalic fistula steal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 653px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical options for bypass revision for brachiocephalic fistula steal are illustrated in the figure.",
"    <br>",
"     (A) Distal revascularization-interval ligation (DRIL):&nbsp;The brachial artery just distal to the anastomosis is ligated, and a bypass&nbsp;is created from the more proximal&nbsp;brachial artery to the&nbsp;proximal radial artery. The distal circulation is dependant upon the new bypass.",
"     <br>",
"      (B) Revision Using Distal Inflow (RUDI): The origin of the fistula is ligated on the venous side followed by&nbsp;a revsion from a more distal arterial source to the venous limb. In contrast to the DRIL procedure, the RUDI procedure&nbsp;maintains the native arterial circulation.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11748=[""].join("\n");
var outline_f11_30_11748=null;
var title_f11_30_11749="Dextromethorphan and chlorpheniramine: Drug information";
var content_f11_30_11749=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dextromethorphan and chlorpheniramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/54/1893?source=see_link\">",
"    see \"Dextromethorphan and chlorpheniramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6803352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coricidin&reg; HBP Cough &amp; Cold [OTC];",
"     </li>",
"     <li>",
"      Dimetapp&reg; Children&rsquo;s Long Acting Cough Plus Cold [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Children&rsquo;s Cough &amp; Cold Long-Acting [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; DM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Softchews&reg; Cough &amp; Runny Nose [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6803356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6803444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General dosing guidelines; consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cough, cold symptoms:",
"     </b>",
"     Oral: Dextromethorphan 30 mg and chlorpheniramine 4 mg every 6 hours as needed (maximum: 120 mg dextromethorphan and 16 mg chlorpheniramine/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6803443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General dosing guidelines; consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cough, cold symptoms:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Liquid: Dextromethorphan 15 mg and chlorpheniramine 2 mg every 6 hours as needed (maximum: 60 mg dextromethorphan and 8 mg chlorpheniramine/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Chewable tablet: Dextromethorphan 10 mg and chlorpheniramine 2 mg every 4-6 hours as needed (maximum: 50 mg dextromethorphan and 10 mg chlorpheniramine/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6803445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6803446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dimetapp&reg; Children&rsquo;s Long Acting Cough Plus Cold: Dextromethorphan hydrobromide 7.5 mg and chlorpheniramine maleate 1 mg per 5 mL (118 mL) [ethanol free, sugar free; contains sodium 3 mg/5 mL, sodium benzoate, propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Children&rsquo;s Cough and Cold Long-Acting: Dextromethorphan hydrobromide 15 mg and chlorpheniramine maleate 2 mg per 5 mL (118 mL) [ethanol free; contains sodium 3 mg/5 mL, sodium benzoate, propylene glycol; fruit punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scot-Tussin&reg; DM Maximum Strength: Dextromethorphan hydrobromide 15 mg and chlorpheniramine maleate 2 mg per 5 mL (118 mL) [ethanol free, dye free, sugar free; cherry-strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coricidin&reg; HBP Cough and Cold: Dextromethorphan hydrobromide 30 mg and chlorpheniramine maleate 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, softchew, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triaminic&reg; Children's Softchews&reg; Cough &amp; Runny Nose: Dextromethorphan hydrobromide 5 mg and chlorpheniramine maleate 1 mg [contains coconut oil, phenylalanine 17.6 mg/softchew, sodium 5 mg/softchew; cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6803354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8105864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triaminic&reg; Children's Softchews&reg; Cough &amp; Runny Nose: Dissolve in mouth or chew prior to swallowing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6803357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of runny nose, sneezing, itchy/watery eyes, cough, and other upper respiratory symptoms associated with hay fever, common cold, or upper respiratory allergies",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6803405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6803360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with or within 14 days of discontinuing MAO inhibitor",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6803361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient&rsquo;s age, the product should",
"     <b>",
"      not",
"     </b>",
"     be administered without the guidance of a physician. Not for OTC use in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Patients with glaucoma or prostatic hyperplasia should consult healthcare provider prior to use. Patients with chronic cough (associated with COPD or smoking) and/or productive cough (eg, copious amounts of phlegm) should be evaluated by a healthcare provider prior to use. Ask healthcare provider prior to using with sedatives. If cough does not improve, is accompanied by rash, fever, or headache, or persists &gt;7 days during use, discontinue use and consult a physician. Do not exceed recommended dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6833606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6803408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6803358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7307784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Child Cough/Cold LA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-7.5 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Cough/Cold Long-Act Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-15 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Scot-Tussin DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-15 mg/5 mL (118 mL): $4.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks NyQuil Childrens Cld/Cgh Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-15 mg/15 mL (236 mL): $7.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Dimetapp Long Act Cough/Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-7.5 mg/5 mL (118 mL): $5.22",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6803411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chlorpheniramine maleate: Antihistamine with H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: A non-narcotic antitussive, increases cough threshold by its activity on the medulla oblongata",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6803413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9013 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11749=[""].join("\n");
var outline_f11_30_11749=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803352\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803356\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803444\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803443\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803445\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803446\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803354\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8105864\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803357\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803405\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803360\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803361\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299163\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6833606\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803408\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803358\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7307784\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321867\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803411\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803413\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9013\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9013|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/54/1893?source=related_link\">",
"      Dextromethorphan and chlorpheniramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_30_11750="Diffuse alopecia areata";
var content_f11_30_11750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Diffuse alopecia areata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse, nonscarring hair loss is present on the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11750=[""].join("\n");
var outline_f11_30_11750=null;
var title_f11_30_11751="VF temporal crescent defect";
var content_f11_30_11751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F79367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F79367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Temporal crescent defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Goldmann visual field showing a left monocular temporal crescent defect",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11751=[""].join("\n");
var outline_f11_30_11751=null;
var title_f11_30_11752="Entecavir in the treatment of chronic hepatitis B virus infection";
var content_f11_30_11752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Entecavir in the treatment of chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/30/11752/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/30/11752/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/30/11752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/30/11752/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/30/11752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/30/11752/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/30/11752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    (Baraclude) is an orally administered cyclopentyl guanosine analogue that has been approved for treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevation in serum aminotransferases or histologically active disease. Approval was based upon the results of three phase 3 trials involving a total of 1633 patients ages 16 and older who had chronic HBV infection, persistently elevated serum ALT levels (&ge;1.3x the upper limit of normal), and chronic inflammation on liver biopsy. Entecavir has also been studied in patients who were refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and in",
"    <span class=\"nowrap\">",
"     HBV/HIV",
"    </span>",
"    coinfected patients.",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of chronic hepatitis B with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    . A general approach to patients with hepatitis B (including other treatment options) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=see_link\">",
"     \"Combination therapy for chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HBeAg-POSITIVE CHRONIC HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    achieves HBeAg seroconversion in about 20 percent of patients with HBeAg positive HBV who have not previously been treated with nucleoside(tide) analogues [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In addition, one-year treatment is associated with a 5 to 7 log(10) reduction in mean HBV DNA levels and corresponding improvement in liver histology. The rate of virological resistance is around 1 percent with up to five years of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Versus lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multinational trial included 715 patients with HBeAg-positive chronic HBV who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    (0.5 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (100 mg daily) for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients were eligible if they had HBV DNA levels &ge;3",
"    <span class=\"nowrap\">",
"     mEq/mL",
"    </span>",
"    (approximately 600,000 int.",
"    <span class=\"nowrap\">",
"     unit/mL),",
"    </span>",
"    a serum ALT &ge;1.3 times the upper limit of normal, compensated liver disease, and had no or &lt;12 weeks of nucleoside(t)e therapy for HBV previously.",
"   </p>",
"   <p>",
"    At week 48, HBeAg seroconversion was observed in 21 percent of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    group and 18 percent of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    group (",
"    <a class=\"graphic graphic_table graphicRef59012 \" href=\"UTD.htm?10/56/11148\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70763 \" href=\"UTD.htm?35/9/35996\">",
"     table 2",
"    </a>",
"    ). Serum HBV DNA decreased from baseline by an average of 6.86 log(10) compared with 5.39 log(10) in the lamivudine group. Suppression of HBV DNA to less than 0.7",
"    <span class=\"nowrap\">",
"     mEq/mL",
"    </span>",
"    (approximately 140,000 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    and normalization of serum ALT were observed significantly more often in the entecavir group (91 versus 65 percent and 78 versus 70 percent, respectively). Serum HBV DNA was undetectable by PCR assay in 67 percent of the entecavir group compared with 36 percent in the lamivudine group.",
"   </p>",
"   <p>",
"    Histologic improvement (defined as &ge;2 point reduction in the Knodell necroinflammatory score) was observed significantly more often in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    group (72 versus 62 percent). Serious adverse events were described in 7 percent of patients in both groups.",
"   </p>",
"   <p>",
"    Treatment was extended until HBeAg loss or up to 96 weeks in a subset of patients who remained HBeAg positive but had HBV DNA less than 0.7",
"    <span class=\"nowrap\">",
"     mEq/mL",
"    </span>",
"    at week 48 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/3\">",
"     3",
"    </a>",
"    ]. At week 96 or earlier (for patients who achieved HBeAg loss before week 96), HBV DNA was undetectable in a larger proportion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    treated patients (80 versus 39 percent). Normalization of ALT was observed in 87 versus 79 percent, and HBeAg seroconversion in 31 versus 25 percent. The safety profile was similar to lamivudine throughout the observation period.",
"   </p>",
"   <p>",
"    Analysis of cumulative responses up to week 96 of all patients originally enrolled into the study found that the proportion of patients achieving HBeAg seroconversion were similar (31 versus 25 percent). However, this analysis did not take into account HBeAg reversion after treatment was stopped.",
"   </p>",
"   <p>",
"    A follow-up report described a subset of 146 patients who received continuous therapy for up to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/4\">",
"     4",
"    </a>",
"    ]. The group was comprised mainly of virologic responders but also included 19 patients who failed to respond during the first year of treatment. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    1 mg daily from year three onward. During years three, four, and five, an increasing proportion of patients achieved and maintained HBV DNA levels &lt;300",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (approximately 60 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    (94 percent by year five). In addition, 33 patients (23 percent) achieved HBeAg seroconversion, and two patients (1.4 percent) lost HBsAg during continued treatment. These data confirm that continued treatment can result in late HBeAg seroconversion in some patients. In a separate follow-up report that focused on 40 HBeAg-positive patients, all of whom achieved HBV DNA levels of &lt;300",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and most of whom had normal aminotransferase levels, treatment with entecavir for five years was associated with a decrease in inflammation as well as fibrosis scores [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/5\">",
"     5",
"    </a>",
"    ]. However, whether these results can be generalized is uncertain since this report included fewer than 10 percent of the original cohort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Versus adefovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    is associated with a greater degree of reduction of HBV DNA than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . An open-label, comparative trial included 69 antiviral-na&iuml;ve patients who were randomly assigned to entecavir (0.5 mg daily) or adefovir (10 mg daily) for a minimum of 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/6\">",
"     6",
"    </a>",
"    ]. The mean HBV DNA change from baseline to week 48 was significantly greater with entecavir (-6.23 versus -4.42 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    In addition, significantly more patients receiving entecavir achieved undetectable (&lt;300",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    HBV DNA levels by PCR between weeks 2 to 48. At 48 weeks, only 3 percent of entecavir treated patients had HBV DNA of 10(5)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    or more compared with 47 percent of adefovir treated patients. These data confirmed that entecavir has more potent antiviral activity than adefovir. Adverse events were similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HBeAg-NEGATIVE CHRONIC HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multinational trial included 648 patients with HBeAg-negative HBV who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    (0.5 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (100 mg daily) for up to 96 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients were eligible if they had HBV DNA &ge;0.7",
"    <span class=\"nowrap\">",
"     mEq/mL",
"    </span>",
"    (approximately 140,000 int.",
"    <span class=\"nowrap\">",
"     unit/mL),",
"    </span>",
"    and ALT level &ge;1.3 times the upper limit of normal, compensated liver disease, and had no or &lt;12 weeks of nucleoside(tide) therapy for HBV previously.",
"   </p>",
"   <p>",
"    The primary efficacy endpoint, histologic improvement, defined as a &ge;2 point reduction in the Knodell necroinflammatory score at 48 weeks, was observed significantly more often in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    group (70 versus 61 percent) (",
"    <a class=\"graphic graphic_table graphicRef59012 \" href=\"UTD.htm?10/56/11148\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70763 \" href=\"UTD.htm?35/9/35996\">",
"     table 2",
"    </a>",
"    ). The mean reduction in HBV DNA was significantly greater in the entecavir group, and undetectable HBV DNA by PCR occurred significantly more often (90 versus 72 percent). Serum HBV DNA decreased by 5.04 log(10) in the entecavir group compared with 4.53 log(10) in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    group. The proportion of patients with ALT normalization was significantly higher in the entecavir group (90 versus 72 percent). Serious adverse events were comparable (6 versus 8 percent). Long-term responses are unclear because most patients were taken off treatment at the end of year one. In a follow-up report, most responders who discontinued treatment after 48 weeks had a relapse of HBV DNA within 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/8\">",
"     8",
"    </a>",
"    ]. In a separate follow-up report that included 17 HBeAg-negative patients, all of whom achieved HBV DNA levels of &lt;300",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and most of whom had normal aminotransferase levels, treatment with entecavir for five years was associated with a decrease in inflammation as well as fibrosis scores [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple prospective and retrospective cohort studies assessing the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    in nucleoside(tide)-na&iuml;ve chronic HBV patients that would not have been included in the initial phase III trials have also demonstrated high rates of virologic and serologic responses and a low incidence of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LAMIVUDINE REFRACTORY HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is less effective against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV mutants as wild type HBV. In vivo studies showed that a higher dose is necessary to suppress lamivudine-resistant HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/12\">",
"     12",
"    </a>",
"    ]. The efficacy of entecavir in patients who have developed resistance to lamivudine was evaluated in a multinational, randomized controlled trial that included 286 patients who were either continued on lamivudine or switched to entecavir (1.0 mg daily) for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients were eligible if they had HBeAg-positive chronic HBV with HBV DNA levels &gt;3",
"    <span class=\"nowrap\">",
"     mEq/mL",
"    </span>",
"    (approximately 600,000 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    and a serum ALT level &ge;1.3 times the upper limit of normal. Patients were considered to be lamivudine refractory if they had persistent viremia while on lamivudine with or without documented mutations in the YMDD motif.",
"   </p>",
"   <p>",
"    At week 48, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    -treated group had a significantly higher rate of HBeAg loss (10 versus 3 percent) and histologic improvement (defined as a &ge;2 point reduction in the Knodell necroinflammatory score, 55 versus 28 percent) (",
"    <a class=\"graphic graphic_table graphicRef74360 \" href=\"UTD.htm?9/35/9788\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80589 \" href=\"UTD.htm?24/7/24699\">",
"     table 4",
"    </a>",
"    ). Serum HBV DNA decreased by 5.11 log(10). Significantly more patients in the entecavir group had undetectable HBV DNA by PCR (21 versus 1 percent) and ALT normalization (75 versus 23 percent). Safety was comparable between the groups, with serious adverse events in 10 and 8 percent of patients in the entecavir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    groups, respectively.",
"   </p>",
"   <p>",
"    The proportion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    -treated patients with undetectable HBV DNA increased from 21 percent at week 48 to 51 percent after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/14\">",
"     14",
"    </a>",
"    ]. These data indicate that entecavir can be beneficial in some patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant HBV, but the antiviral activity is substantially lower compared with wild type HBV, even with the 1.0 mg dose. Drug resistance is of increasing concern with longer durations of treatment and entecavir should not be used in patients with lamivudine resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADEFOVIR REFRACTORY HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    in patients who did not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . One series included 15 HBeAg-positive patients who had an HBV viral load above 5 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    after one year of adefovir and were treated with entecavir (1 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/15\">",
"     15",
"    </a>",
"    ]. Eight patients had also received previous therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . No patient who had received prior lamivudine achieved undetectable HBV DNA while on entecavir. Of the six lamivudine-na&iuml;ve patients, serum HBV DNA decreased by 2.9 and 3.4 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    after 6 and 12 months of switching to entecavir, but only one achieved undetectable HBV DNA. These data suggest that entecavir may result in further decrease in serum HBV DNA in HBeAg-positive patients with a partial virologic response to adefovir.",
"   </p>",
"   <p>",
"    Another report included 50 patients with compensated chronic HBV (80 percent HBeAg positive) who developed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    resistant mutations during adefovir monotherapy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -refractory HBV and were switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/16\">",
"     16",
"    </a>",
"    ]. Only 22 percent of patients achieved a complete virologic response (defined as HBV DNA &lt;60 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    after 12 months.",
"   </p>",
"   <p>",
"    These data indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    has greater antiviral activity in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    -refractory HBV who are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -na&iuml;ve than those who are lamivudine-experienced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HIV COINFECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    in HIV coinfected patients is limited. Although the original package insert for entecavir indicated no anti-HIV activity by in vitro testing at clinically relevant concentrations, a one-log drop in HIV RNA was reported in three separate patients who were taking entecavir monotherapy. One of these three patients was also shown to have selection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant M184V HIV variant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/17\">",
"     17",
"    </a>",
"    ]. Data from this study and subsequent studies show that entecavir should not be used in HIV-HBV co-infected patients who are not receiving fully suppressive antiretroviral regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84530367\">",
"    <span class=\"h1\">",
"     SEVERE EXACERBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little published experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    for the management of severe exacerbations of chronic HBV. One of the largest series included 36 patients considered to have a severe exacerbation because of an increase in serum alanine aminotransferase levels more than 10 times the upper limit of normal with an increase in total bilirubin levels more than three times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients received entecavir for 48 weeks. Compared with a group of 117 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    for a severe exacerbation, the patients who received entecavir had an unexpectedly increased risk of prolonged jaundice, hepatic encephalopathy, ascites, and early mortality. However, this difference may be related to the small number of patients, the older age, and more advanced liver disease in the entecavir group. The authors' suggestion that rapid viral suppression may be deleterious in patients with severe exacerbation is not substantiated by another larger study in patients with decompensated cirrhosis showing that a more rapid viral response with entecavir compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    was associated with a similar if not better outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/19\">",
"     19",
"    </a>",
"    ]. We recommend initiating antiviral therapy as soon as possible in patients with severe exacerbation. Interferon should not be used in this setting. Given the need for long-term therapy, we recommend entecavir or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DECOMPENSATED CIRRHOSIS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study included 70 treatment-na&iuml;ve patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      (0.5 mg daily) for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/20\">",
"       20",
"      </a>",
"      ]. During the course of follow-up, 15 patients dropped out (nine because of death or the need for liver transplantation, and six were lost to follow-up). Of the remaining 55 patients, 49 percent had improvement in Child-Turcotte Pugh score of &ge;2 points. On intention-to-treat analysis, 92 percent became HBV DNA negative, and 54 percent lost HBeAg. Adverse events were not discussed.",
"     </li>",
"     <li>",
"      Another study included 191 patients with decompensated HBV who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      (1 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      (10 mg daily) for up to 96 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/19\">",
"       19",
"      </a>",
"      ]. The entecavir group had a greater decline in HBV DNA levels and was more likely to achieve an HBV DNA level of &lt;300",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (57 versus 20 percent at week 48). About two-thirds of patients in both groups showed either improvement or stabilization in Child-Turcotte-Pugh status. Adverse events were similar between the groups.",
"     </li>",
"     <li>",
"      A third report included 112 patients with decompensated liver disease who were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , tenofovir plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      in a phase II study designed to evaluate safety [",
"      <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/21\">",
"       21",
"      </a>",
"      ]. All three treatments were well-tolerated and were associated with improvement in virological, biochemical, and clinical features.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In case reports,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    has been associated with severe lactic acidosis when used in patients with decompensated cirrhosis. Lactic acidosis may be a class effect of nucleosides and may be related to sepsis, which occurs commonly in hospitalized patients with decompensated cirrhosis. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENTS WITH LOW ALT LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the management of chronic HBV recognize that the degree of elevation of serum aminotransferases is predictive of the likelihood of response. Patients with low ALT levels who are in the immune tolerant phase of infection tend to respond less well than those with elevated ALT levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    in patients with a low ALT level has not been extensively studied. However, a subset analysis that included 336 patients who had been treated as part of a randomized controlled trial of entecavir and whose ALT was 1.3 to 2 times the upper limit of normal found that responses among HBeAg-negative patients were similar to those with higher ALT levels, while they were significantly lower in HBeAg-positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these data suggest a potential benefit of treatment in patients with minimally elevated ALT, most patients will require many years of treatment to achieve the desired therapeutic endpoint. More studies are needed to determine whether the benefits of initiating treatment in patients with minimally elevated ALT on clinical outcomes are superior to deferring treatment until patients have higher ALT (eg, &gt;2 times upper limit of normal), particularly in HBeAg-positive patients. Until further data are available, the decision to initiate treatment for patients with mildly elevated ALT levels should be individualized and will be influenced by the severity of liver disease based on liver biopsy findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    appears to occur through a 2-hit mechanism. Initially, mutants that are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    <span class=\"nowrap\">",
"     (rtM204V/I)",
"    </span>",
"    are selected because they are less sensitive to entecavir. During continued treatment, additional mutations at rtI169, rtT184, rtS202,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rtM250 are selected [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Entecavir resistant strains appear to be sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No resistance was observed after 48 weeks of treatment in the two large multinational trials of nucleoside-na&iuml;ve patients described above [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. As noted above, one patient had a breakthrough infection after five years in a follow-up report of a controlled trial of HBeAg-positive HBV, while two patients with HBeAg-negative HBV developed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    resistance after two years in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/8,26\">",
"     8,26",
"    </a>",
"    ]. Resistance was observed in only 0.4 percent of patients in a study of 474 patients (47 percent HBeAg positive) followed for four years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report from the manufacturer updated resistance analysis in patients who had received up to five years of treatment. In nucleoside-na&iuml;ve patients, genotypic resistance and virologic breakthrough were observed in 1.2 and 0.8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/28\">",
"     28",
"    </a>",
"    ]. By contrast, genotypic resistance rates were much higher in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance; in such patients, the five-year cumulative probability of genotypic resistance and virologic breakthrough were 51 and 43 percent, respectively.",
"   </p>",
"   <p>",
"    These data indicate that resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is rare (approximately 1 percent after five years treatment) in nucleoside-na&iuml;ve patients but common (approximately 50 percent after five years treatment) in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -refractory patients. However, there were problems with the trial design in nucleoside-na&iuml;ve patients. In the trial in HBeAg-positive patients, a small number of nonresponders (serum HBV DNA &gt;0.7",
"    <span class=\"nowrap\">",
"     mEq/mL)",
"    </span>",
"    were not included in the analysis. In the trial in HBeAg-negative patients, most patients had interruption of treatment in year two. Furthermore, a higher dose of entecavir 1.0 mg was used after year two. Despite these limitations, entecavir monotherapy appears to be associated with a very low rate of drug resistance up to five years of treatment in nucleoside-na&iuml;ve patients, but the rate of drug resistance in lamivudine-refractory patients is unacceptably high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is comparable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    during 48 weeks of treatment. The overall rate of serious adverse events was 7 percent in treatment-na&iuml;ve patients and 10 percent in lamivudine-refractory patients. The most frequent adverse events (observed in about 84 percent of patients) were generally of mild-to-moderate severity and included headache, upper respiratory tract infection, cough, nasopharyngitis, fatigue, and upper abdominal pain. Entecavir was discontinued due to an adverse event or laboratory test result in only 1 percent of patients (compared with 4 percent in lamivudine-treated patients). On treatment flares (defined as an ALT &gt;10X the upper limit of normal) were observed in 2 and 4 percent of nucleoside-na&iuml;ve patients treated with entecavir and lamivudine, respectively. Corresponding values in lamivudine-refractory patients were 2 and 11 percent, respectively. ALT flares after discontinuation of treatment (defined as an ALT &gt;10X the upper limit of normal) were observed in a similar proportion of entecavir and lamivudine-treated patients (6 versus 10 percent).",
"   </p>",
"   <p>",
"    The following adverse events were observed in a study of 1051 patients who were exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    for a median of 3.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most adverse events were considered to be mild to moderate",
"     </li>",
"     <li>",
"      4 percent of adverse events were considered attributable to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"     </li>",
"     <li>",
"      On-treatment ALT flares occurred in 3 percent of patients",
"     </li>",
"     <li>",
"      1 percent of patients discontinued treatment due to an adverse event",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe lactic acidosis has been reported in a case series of patients with advanced cirrhosis (MELD score &ge;20) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/30\">",
"     30",
"    </a>",
"    ]. Lactic acid level was not monitored in several trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    in patients with decompensated cirrhosis, but clinical manifestations suggestive of severe lactic acidosis were not observed. Entecavir should be used with caution in patients with decompensated liver disease.",
"   </p>",
"   <p>",
"    Studies in mice found an increased risk of lung adenomas (at exposures 3 to 40 times those in humans). In addition, hepatocellular carcinomas were increased in male mice, while brain gliomas were induced in male and female rats. Whether these observations have relevance to humans is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose for nucleoside-na&iuml;ve patients is 0.5 mg daily and for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    refractory patients 1.0 mg daily. The manufacturer recommends adjustment of the dose in patients with a creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    including patients on hemodialysis or continuous ambulatory peritoneal dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OPTIMAL DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is unknown. The design of the phase III trials did not include a large enough number of patients who received continued treatment beyond year one to assess long-term response. Among HBeAg-positive patients who had HBeAg seroconversion, the response was sustained through week 24 post-treatment in 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/31\">",
"     31",
"    </a>",
"    ]. Among patients who had not previously been treated with a nucleoside(tide) analogue, persistence of detectable HBV DNA after 48 weeks of treatment does not necessarily mandate an alteration of therapy. In one report of such patients, more than 90 percent ultimately achieved undetectable HBV DNA levels with continued treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon studies with other oral therapies for HBV, long-term treatment will likely be required to obtain a sustained benefit in most patients. Notably, long-term therapy has been associated with the reversal of fibrosis and cirrhosis in case series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11752/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      (0.5 mg daily for 52 weeks) in patients with HBeAg-positive or HBeAg-negative chronic HBV infection was associated with a 5 to 7 log(10) reduction in mean HBV DNA levels. This degree of reduction is greater than what has been observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      dipivoxil or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      but appears to be similar to that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'HBeAg-positive chronic hepatitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'HBeAg-negative chronic hepatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      -resistant chronic HBV infection,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      (1 mg daily for 52 weeks) was more effective than continued lamivudine therapy in achieving a reduction of HBV DNA, ALT normalization, and histologic improvement. However, entecavir is less effective against lamivudine-resistant HBV with lower rates of response and higher rates of resistance. Entecavir is not recommended for patients with lamivudine resistant HBV. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lamivudine refractory HBV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recommended dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      is 0.5 mg once daily for nucleoside-na&iuml;ve adults and adolescents older than 16, while it is 1 mg daily for those who have persistent HBV viremia while receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or have known lamivudine resistance. The dose should be adjusted in patients with a creatinine clearance of &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      as noted above. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      is rare (approximately 1 percent after five years treatment) in nucleoside-na&iuml;ve patients but common (approximately 50 percent after five years treatment) in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      -refractory patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An approach to treatment of HBV that considers all the available treatment options in various settings is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"       \"Overview of the management of hepatitis B and case examples\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/1\">",
"      Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-na&iuml;ve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/2\">",
"      Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/3\">",
"      Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/4\">",
"      Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/5\">",
"      Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/6\">",
"      Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 49:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/7\">",
"      Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/8\">",
"      Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/9\">",
"      Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of na&iuml;ve patients with a partial virological response. Hepatology 2011; 54:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/10\">",
"      Ridruejo E, Adrover R, Cocozzella D, et al. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract 2011; 65:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/11\">",
"      Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012; 19:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/12\">",
"      Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/13\">",
"      Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039.",
"     </a>",
"    </li>",
"    <li>",
"     Tenney DJ, Pokorowski KA, Rose RE, et al. Entecavir at five years shows long long-term maintenance of high genetic barrier to hepatitis B virus resistance. Conference of the Asia-Pacific Association for the Study of the Liver (APASL) 2008, Seoul, Korea.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/15\">",
"      Reijnders JG, Pas SD, Schutten M, et al. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/16\">",
"      Heo NY, Lim YS, Lee HC, et al. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/17\">",
"      Jain MK, Zoellner CL. Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) na&iuml;ve patient treated for chronic HBV. AIDS 2007; 21:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/18\">",
"      Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011; 54:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/19\">",
"      Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/20\">",
"      Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-na&iuml;ve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/21\">",
"      Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/22\">",
"      Wu IC, Lai CL, Han SH, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/23\">",
"      Colonno RJ, Rose RE, Pokornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients (abstract). Hepatology 2006; 44 (Suppl 1):229A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/24\">",
"      Warner N, Locarnini SA, Edwards R, et al. Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy (abstract). Hepatology 2004; 40 (Suppl 1):245A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/25\">",
"      Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48:3498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/26\">",
"      Han S, Chang TT, Chao YC, et al. Four-years of continuous entecavir for nucleoside-na&iuml;ve HBeAg(+) chronic hepatitis B: results from study ETV-901 (abstract). Hepatology 2008; (Suppl):705A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/27\">",
"      Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-na&iuml;ve chronic hepatitis B patients. J Hepatol 2012; 57:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/28\">",
"      Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-na&iuml;ve patients is rare through 5 years of therapy. Hepatology 2009; 49:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/29\">",
"      Manns MP, Akarca US, Chang TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012; 11:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/30\">",
"      Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/31\">",
"      Chang TT, Chao YC, Kaymakoglu S, et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-na&iuml;ve HBeAg(+) patients (ETV 022/901) (abstract). Hepatology 2006; 44:229A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11752/abstract/32\">",
"      Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9:274.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3653 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-0E8DCFA2F5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11752=[""].join("\n");
var outline_f11_30_11752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HBeAg-POSITIVE CHRONIC HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Versus lamivudine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Versus adefovir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HBeAg-NEGATIVE CHRONIC HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LAMIVUDINE REFRACTORY HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADEFOVIR REFRACTORY HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HIV COINFECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84530367\">",
"      SEVERE EXACERBATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DECOMPENSATED CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENTS WITH LOW ALT LEVELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OPTIMAL DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3653|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/56/11148\" title=\"table 1\">",
"      Entecavir versus lamivudine I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/9/35996\" title=\"table 2\">",
"      Entecavir versus lamivudine II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/35/9788\" title=\"table 3\">",
"      Entecavir lamiv refractory I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/7/24699\" title=\"table 4\">",
"      Entecavir lamiv refractory II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=related_link\">",
"      Combination therapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_30_11753="Blood vessels of the anterior abdominal wall";
var content_f11_30_11753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Blood vessels of the anterior abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 707px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The superior and inferior epigastric arteries provide a rich arcade, arising from the internal thoracic artery superiorly and the external iliac artery inferiorly. The musculophrenic artery, deep circumflex iliac artery and subcostal arteries supply the lateral abdominal wall. The superficial epigastric veins and the superficial iliac veins can arise from the great saphenous vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11753=[""].join("\n");
var outline_f11_30_11753=null;
var title_f11_30_11754="Sedation or induction agents for rapid sequence intubation in adults";
var content_f11_30_11754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sedation or induction agents for rapid sequence intubation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/30/11754/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/30/11754/contributors\">",
"     David Caro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/30/11754/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/30/11754/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/30/11754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/30/11754/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/30/11754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first task of any clinician managing an acutely unstable patient is to secure the airway. In most circumstances, emergency clinicians use rapid sequence intubation (RSI) to accomplish this task. RSI incorporates a rapidly acting sedative (ie, induction) agent, in addition to a neuromuscular blocking (ie, paralytic) agent, to create optimal intubating conditions. Selection of the sedative agent and dose most appropriate for the clinical scenario is an important component of RSI.",
"   </p>",
"   <p>",
"    The pharmacology and selection of induction agents for use in RSI will be reviewed here. The techniques and other medications used in the performance of RSI, as well as other aspects of airway management, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=see_link\">",
"     \"Pretreatment agents for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RAPID SEQUENCE INTUBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid sequence intubation (RSI) is the standard of care in emergency airway management for intubations not anticipated to be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. RSI is the virtually simultaneous administration of a sedative and a neuromuscular blocking agent to render a patient rapidly unconscious and flaccid in order to facilitate emergent endotracheal intubation and to minimize the risk of aspiration. Multiple studies confirm the high-success rate of RSI using the combination of a sedative and a paralytic drug [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDUCTION AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction agents (sedatives) are integral to the performance of rapid sequence intubation (RSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/5\">",
"     5",
"    </a>",
"    ]. They provide amnesia, blunt sympathetic responses, and can improve intubating conditions.",
"   </p>",
"   <p>",
"    When a paralytic agent is used for intubation without sedation, the patient may be fully aware of his or her environment, including pain, but unable to respond [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. In addition to its inhumanity, this circumstance allows for potentially adverse physiologic responses to airway manipulation, including tachycardia, hypertension, and elevated intracranial pressure (ICP) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/10\">",
"     10",
"    </a>",
"    ]. Sedative use prevents or minimizes these effects. Furthermore, clinicians can sometimes select an induction agent that both facilitates RSI and ameliorates the patient's underlying condition. As examples,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    can be used in status epilepticus for its anticonvulsant properties and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    in severe asthma to reduce bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of sedatives may also improve the laryngoscopic view obtained during RSI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/5,12,13\">",
"     5,12,13",
"    </a>",
"    ]. During RSI, the clinician must perform laryngoscopy during the earliest phase of neuromuscular paralysis. Sedatives improve laryngoscopy in part by supplementing the yet incomplete relaxation provided by the paralytic. Even in the presence of a full neuromuscular blocking dose of a paralytic, the addition of a sedative improves intubating conditions during RSI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each of the major induction agents in common use is discussed below (",
"    <a class=\"graphic graphic_table graphicRef64272 \" href=\"UTD.htm?35/29/36316\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Etomidate",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     General use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    is an imidazole-derived, sedative-hypnotic agent that is frequently used for rapid sequence intubation (RSI). Etomidate acts directly on the gamma amino butyric acid (GABA) receptor complex, blocking neuroexcitation and producing anesthesia. Etomidate is given by intravenous push in a dose of 0.3",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    with a time to effect of 15 to 45 seconds and a duration of action of 3 to 12 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/14\">",
"     14",
"    </a>",
"    ]. It is the most hemodynamically neutral of the sedative agents used for RSI, and does not stimulate histamine release [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/15-21\">",
"     15-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    provides no analgesic effect, so it does not blunt the noxious stimulation of the upper airway during laryngoscopy and intubation. For patients in whom this is a concern (eg, patients with cardiovascular disease or elevated intracranial pressure), an opioid analgesic, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , is often given during the pretreatment phase of RSI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hemodynamic stability associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    makes it the drug of choice for the intubation of hypotensive patients, as well as an attractive option for patients with intracranial pathology, when hypotension must be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/15-19,21\">",
"     15-19,21",
"    </a>",
"    ]. Etomidate causes a mild increase in airway resistance, but less so than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    , and may be used in patients with bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    include adrenal suppression (discussed below), myoclonus, and evidence of regional cerebral excitation (determined by electroencephalogram) after intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/18,24,25\">",
"     18,24,25",
"    </a>",
"    ]. Myoclonus has been misidentified as seizure activity, leading to incorrect recommendations that etomidate be avoided in patients with seizure disorders. Myoclonus during RSI is brief and minimal, because of the concomitant administration of a paralytic agent, and of no clinical significance. Etomidate decreases cerebral blood flow and cerebral metabolic oxygen demand, while preserving cerebral perfusion pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/21\">",
"     21",
"    </a>",
"    ]. Postintubation sedation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    or benzodiazepines helps to prevent neuroexcitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adrenocortical suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major controversy surrounding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    stems from the reversible adrenocortical suppression associated with its use [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Etomidate is a reversible inhibitor of 11-beta-hydroxylase, which converts 11-deoxycortisol to cortisol (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    causes a measurable decrease in the level of circulating cortisol that occurs in response to the administration of exogenous ACTH, although cortisol levels do not fall below the normal physiologic range. This effect does not persist beyond 12 to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some researchers have raised concerns regarding the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    in the setting of adrenal insufficiency related to sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/27,28,30\">",
"     27,28,30",
"    </a>",
"    ]. However, no well-designed, prospective trial has shown adverse effects from a single dose of etomidate used for intubation in patients with sepsis or septic shock.",
"   </p>",
"   <p>",
"    A multicenter randomized trial of critically ill patients requiring emergent intubation found no significant difference in organ failure score, 28 day mortality, or intubating conditions between patients given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    for induction and those given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/31\">",
"     31",
"    </a>",
"    ]. No serious, drug-related adverse events were reported for either medication. Although adrenal insufficiency occurred at a higher rate in the etomidate group (86 percent), it also developed in approximately 48 percent of patients receiving ketamine.",
"   </p>",
"   <p>",
"    A systematic review of 20 studies in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    was given in a bolus dose as part of induction for tracheal intubation found that etomidate does not have a significant effect upon mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/32\">",
"     32",
"    </a>",
"    ]. Declines in serum cortisol concentrations were more prevalent among etomidate recipients than those who did not receive etomidate in the large majority of studies, but did not persist beyond five hours. The authors note that no individual study included in the review was sufficiently powered to detect differences in mortality or resource utilization.",
"   </p>",
"   <p>",
"    Less rigorous individual studies, and flawed reviews based upon such studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/33\">",
"     33",
"    </a>",
"    ], have reported mixed results that do not justify recommendations to avoid using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    for induction in patients with sepsis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small observational study of children with meningococcal sepsis reported a correlation between the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      for RSI and low cortisol levels, which increased the risk of death [",
"      <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/27\">",
"       27",
"      </a>",
"      ]. This retrospective study did not randomize patients by intubating sedative agent, nor did it differentiate patients who were intubated from those (presumably less ill) who did not require intubation. The study had several other limitations, including the small number of nonsurvivors (n = 8) and the younger age and more severe disease among nonsurvivors.",
"     </li>",
"     <li>",
"      A prospective observational study of 106 patients who met sepsis criteria and were intubated found no increase in mortality among those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      (n = 74) compared with those who received an alternative or no induction agent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/34\">",
"       34",
"      </a>",
"      ]. No differences were identified in the severity of illness or the demographic characteristics of the two groups.",
"     </li>",
"     <li>",
"      An observational study using data from the CORTICUS trial reported increased mortality among patients with septic shock who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      for intubation [",
"      <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/35\">",
"       35",
"      </a>",
"      ]. However, this study is limited and cannot demonstrate causality. According to the authors: \"This study&hellip;was not designed or powered to test the outcomes prospectively. We do not know the patient's [sic] severity of illness at the time etomidate was used.\" Furthermore, a mortality difference did not appear until 10 days after etomidate was used and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      made no difference in outcome, making it unlikely that etomidate accounts for the difference described.",
"     </li>",
"     <li>",
"      Several retrospective studies, published subsequently to the systematic review described above, of patients with severe sepsis or septic shock who received a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      as part of RSI have reported no increase in mortality, vasopressor use, or ICU length of stay [",
"      <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    has the advantages of superior hemodynamic stability, when compared with most other sedative or induction agents and familiarity because of its widespread use for RSI. When intubating the critically ill patient with possible adrenal insufficiency, the clinician must weigh the theoretical risk of cortisol suppression against the hemodynamic instability that may be caused by alternative induction agents.",
"   </p>",
"   <p>",
"    We recognize the critical importance of maintaining adequate blood pressure early in the treatment of sepsis and, pending more definitive studies, we believe that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    is an acceptable induction agent for patients with severe sepsis.",
"   </p>",
"   <p>",
"    In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used as an infusion or in repeated bolus doses for maintenance of sedation after intubation. Thus, emergency clinicians should inform the physicians assuming care for the patient in the intensive care unit if etomidate has been used for induction. If ACTH stimulation testing is being considered, clinicians should be aware that the results may be affected by prior administration of etomidate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authors recommend the use of empiric glucocorticoids for the first 24 hours after a dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    in patients with sepsis, but this approach lacks support from outcome studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/27,38\">",
"     27,38",
"    </a>",
"    ]. We suggest that patients with sepsis who receive etomidate for RSI also receive a single dose of glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    100 mg IV)",
"    <strong>",
"     only",
"    </strong>",
"    if they manifest hypotension that is refractory to treatment with aggressive fluid resuscitation and a vasopressor. This approach is consistent with that used for patients who do not receive etomidate. A discussion of the role of glucocorticoids in septic shock is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"     \"Corticosteroid therapy in septic shock\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines cause sedation and amnesia through their effects on the gamma amino butyric acid (GABA) receptor complex.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    is the most rapidly acting, making it the benzodiazepine of choice for rapid sequence intubation (RSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The induction dose for midazolam is 0.1 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV push, with a time to effect of approximately 30 to 60 seconds, and a duration of action of 15 to 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like all benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    does not provide analgesia but does possess anticonvulsant effects, making it an effective agent for RSI in patients with status epilepticus.",
"   </p>",
"   <p>",
"    The routine induction dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    for RSI is 0.2",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    In this dose, midazolam causes moderate hypotension, with an average drop in mean arterial blood pressure in healthy patients of 10 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This tendency to induce hypotension limits midazolam's usefulness in the setting of hypovolemia or shock. If midazolam must be used in such patients, we suggest a dose of 0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    which will somewhat delay the speed of onset and the depth of sedation achieved, but should not severely compromise intubating conditions. For patients in shock, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    because of their superior hemodynamic profiles. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etomidate'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Ketamine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    is frequently underdosed (common dose 0.05",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    when used for emergency department RSI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/41\">",
"     41",
"    </a>",
"    ]. Midazolam is often used for procedural sedation in much smaller doses than are required for RSI, which may contribute to underdosing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    can be used as an infusion for long-term sedation. Doses of 0.05 to 0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour IV have been shown to be safe and effective in critically ill neonates and children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], including neonates undergoing extracorporeal membrane oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/44\">",
"     44",
"    </a>",
"    ]. Dosing in intubated adults should be titrated to an endpoint of adequate sedation, preferably using a sedation scale.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    are benzodiazepines used frequently for long-term sedation following intubation, but are not recommended for RSI. Both require propylene glycol as a diluent, and there are reports of propylene glycol toxicity associated with long-term infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=see_link&amp;anchor=H2#H2\">",
"     \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\", section on 'Benzodiazepines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultrashort-acting barbiturates interact with the barbiturate component of the GABA receptor complex, causing profound amnesia and sedation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     Thiopental",
"    </a>",
"    sodium is the barbiturate most commonly used for rapid sequence intubation (RSI). The induction dose is 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, with a time to effect of less than 30 seconds, and a duration of action of 5 to 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/46\">",
"     46",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     Methohexital",
"    </a>",
"    is another barbiturate used for induction; its induction dose is 1 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, with a time to effect of less than 30 seconds, and a duration of action of approximately 5 to 10 minutes. Barbiturates do not provide analgesia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     Thiopental",
"    </a>",
"    suppresses neuronal activity, making it a useful induction agent in hemodynamically stable patients with conditions that can elevate intracranial pressure (ICP), including seizures, intracranial bleeding, or trauma.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     Thiopental",
"    </a>",
"    is a venodilator with negative cardiac inotropic effects, and can induce profound hypotension in the doses used for induction of anesthesia. Clinicians must exercise great care when using it in hemodynamically unstable patients or patients prone to hypotension, such as the elderly. For emergency department RSI, we recommend a dose of 3",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    A reduced dose of 2 or 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is recommended in the setting of hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/47\">",
"     47",
"    </a>",
"    ]. Reductions in ICP associated with thiopental may be caused in part by a decrease in mean arterial pressure, which decreases cerebral perfusion.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     Thiopental",
"    </a>",
"    causes histamine release and can induce or exacerbate bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/48\">",
"     48",
"    </a>",
"    ]. We recommend that thiopental not be used in patients with reactive airway disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     Thiopental",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/15/24823?source=see_link\">",
"     methohexital",
"    </a>",
"    suppress white blood cell recruitment, activation, and activity, both in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/49,50\">",
"     49,50",
"    </a>",
"    ] and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. This effect has been attributed to a number of causes, including suppression of nuclear transcription factor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/54\">",
"     54",
"    </a>",
"    ], an increase in apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/49\">",
"     49",
"    </a>",
"    ], and a decrease in phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/50\">",
"     50",
"    </a>",
"    ]. These immunosuppressive effects make barbiturates poor induction agents in the setting of sepsis, and we do not recommend their use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ketamine",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     General use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is a dissociative anesthetic agent, structurally similar to phencyclidine (PCP). It is unique among sedative agents in that it provides analgesia along with its amnestic and sedative effects. Ketamine is given intravenously in doses of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    with a time to effect of 45 to 60 seconds, and a duration of action of 10 to 20 minutes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    acts at many receptors causing a range of effects. It is thought to stimulate the N-methyl-D-aspartate receptor at the GABA receptor complex, causing neuroinhibition and anesthesia. It excites opioid receptors within the insular cortex, putamen, and thalamus, producing analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. It stimulates catecholamine receptors and release of catecholamines leading to increases in heart rate, contractility, mean arterial pressure, and cerebral blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/55,57-59\">",
"     55,57-59",
"    </a>",
"    ]. Ketamine decreases the production of vascular nitric oxide, diminishing its vasodilatory effect [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/60\">",
"     60",
"    </a>",
"    ], and inhibits nicotinic acetylcholine receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    preserves respiratory drive and has both a quick onset of action and analgesic properties. This makes it a good choice for \"awake\" intubation attempts, when laryngoscopy is performed on a patient who is moderately sedated and topically anesthetized but not paralyzed due to concerns about a difficult airway. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Conditions precluding use of a paralytic'",
"    </a>",
"    below.) Ketamine causes sympathetic stimulation, and is the most hemodynamically stable of all of the available sedative induction agents, making it an attractive choice for hypotensive patients requiring rapid sequence intubation (RSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Ketamine has also been used successfully and safely in an infant population undergoing bronchoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Theoretically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    causes bronchodilation by stimulating the release of catecholamines. Limited evidence from animal studies suggests the drug may also have direct bronchodilatory effects. Although definitive evidence is lacking, many clinicians use ketamine as an induction agent in severe asthmatics needing RSI. Use of ketamine infusions in subanesthetic doses during asthma exacerbations provides no additional benefit compared with standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/59\">",
"     59",
"    </a>",
"    ]. Case reports suggest larger doses may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    appears to have beneficial effects on stunned myocardium in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/58\">",
"     58",
"    </a>",
"    ]. When used prior to myocardial oxygen deprivation, ketamine resulted in better recovery after reperfusion. Contractility may also improve with ketamine use [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/57\">",
"     57",
"    </a>",
"    ]. Clinicians must weigh ketamine's potential cardiovascular benefits against its potential to induce cardiac ischemia in patients with significant coronary disease.",
"   </p>",
"   <p>",
"    The reemergence phenomenon, in which patients experience disturbing dreams as they emerge from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    -induced anesthesia, limits use of the drug for procedural sedation or elective anesthesia in adult patients. Reemergence phenomena are of less concern when ketamine is used for RSI, after which the patient is generally sedated with benzodiazepines for a substantial period. One study found that while dreams occurred frequently following sedative doses of ketamine, they were generally pleasant, and the frequency of reemergence phenomena and delirium was markedly reduced by concomitant use of a benzodiazepine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Elevated intracranial pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy persists regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    in patients with a head injury due to concerns about elevating intracranial pressure (ICP). Opponents emphasize that ketamine can cause a rise in ICP through sympathetic stimulation, potentially exacerbating the condition of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. However, when ketamine is used with a GABA agonist, this rise in ICP may not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Furthermore, by increasing cerebral perfusion, ketamine may benefit patients with a neurologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/55,66\">",
"     55,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, eight patients with traumatic brain injury and elevated ICP's, sedated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , were given different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    (1.5, 3, or 5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/67\">",
"     67",
"    </a>",
"    ]. ICP monitoring revealed an initial decline in ICP in all three groups, then slight ICP elevations at varying times in the lowest and highest dose groups (23 percent rise at 10 minutes in the 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group; 27 percent rise at 30 minutes in the 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group), but none in the intermediate dose group. Ketamine did not alter cerebral hemodynamics at any time.",
"   </p>",
"   <p>",
"    In another study, researchers randomly assigned 25 patients with traumatic brain injury (TBI) to sedation with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/47/15094?source=see_link\">",
"     sufentanil",
"    </a>",
"    and midazolam [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/68\">",
"     68",
"    </a>",
"    ]. No significant differences in intracranial pressure or cerebral perfusion pressure were observed. A similar study of 24 patients with TBI or subarachnoid hemorrhage compared ketamine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and found similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    does not interfere with cerebral metabolism; it does not increase cerebral oxygen consumption and does not reduce regional glucose metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/55,70\">",
"     55,70",
"    </a>",
"    ]. Ketamine can also offset any decrease in mean arterial pressure caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , a drug commonly used as part of RSI in patients with a head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On balance, evidence suggesting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    elevates ICP is weak, and evidence that harm might ensue is weaker. We believe ketamine is an appropriate induction agent for RSI in patients with suspected ICP elevation and normal blood pressure or hypotension. In patients with hypertension and suspected ICP elevation, ketamine should be avoided because of its tendency to further elevate blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Propofol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is a highly lipid-soluble, alkylphenol derivative that acts at the GABA receptor causing sedation and amnesia. Sedation occurs through direct suppression of brain activity, while amnesia appears to result from interference with long-term memory creation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Induction doses of 1.5 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV can be used, with a time to effect of approximately 15 to 45 seconds, and a duration of action of 5 to 10 minutes. Propofol does not provide analgesia.",
"   </p>",
"   <p>",
"    The pharmacokinetic properties of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    do not appear to differ among races or between genders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], but children appear to have a slightly longer time to peak serum concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    reduces airway resistance and can be a useful induction agent for patients with bronchospasm undergoing RSI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/23,76,77\">",
"     23,76,77",
"    </a>",
"    ]. Its neuroinhibitory effects make propofol a good induction agent for patients with intracranial pathology, provided they are hemodynamically stable. Propofol suppresses sympathetic activity, causing myocardial depression and peripheral vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. A decrease in mean arterial pressure (MAP) caused by propofol can reduce cerebral perfusion pressure, thereby exacerbating a neurologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/82\">",
"     82",
"    </a>",
"    ]. The usual decrease in MAP is approximately 10 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    does not prolong the QT interval, unlike some other anesthetic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Serum triglycerides and serum lipase rise during propofol infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/86\">",
"     86",
"    </a>",
"    ]. Although the manufacturer lists egg or soybean allergies as contraindications to the use of propofol, significant allergic reactions to the newer preparation of the drug appear to be rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=see_link&amp;anchor=H9#H9\">",
"     \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\", section on 'Hypnotic induction agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHOICE OF INDUCTION AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different clinical scenarios lend themselves to the use of certain induction agents when rapid sequence intubation (RSI) is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Head injury or stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with potentially elevated intracranial pressure (ICP) from head injury or stroke or other conditions, adequate cerebral perfusion pressure must be maintained to prevent secondary brain injury. This means avoiding elevations in ICP and maintaining adequate mean arterial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/47\">",
"     47",
"    </a>",
"    ]. For these reasons, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    be used for induction of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etomidate'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Ketamine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the patient is hypertensive at the time of induction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    is preferable, as it will not further elevate the blood pressure. In normotensive or hypotensive patients, either agent can be used. In the severely hypotensive patient,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    is preferable. Ketamine's analgesic effects minimize the adverse sympathetic stimulation of laryngoscopy, while etomidate lacks such effect.",
"   </p>",
"   <p>",
"    We suggest pretreatment with a low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    given three minutes before the induction agent) for patients with suspected elevated ICP, particularly if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    is to be used for sedation, to mitigate catecholamine release caused by laryngoscopy. If the patient is hypotensive, however, fentanyl should be avoided.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    , barbiturates, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    have been used in head-injured patients, but the risk of hypotension-induced brain injury must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/5,20,52,82,87-89\">",
"     5,20,52,82,87-89",
"    </a>",
"    ]. If these agents are used, the dose should be reduced to minimize the risk of hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Status epilepticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    be used for the rapid sequence intubation (RSI) of patients in status epilepticus. Reduced doses should be used in the unusual circumstance of seizure with hypotension.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is acceptable.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    can cause myoclonus, and has a slightly higher rate of EEG-documented seizure activity compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/28\">",
"     28",
"    </a>",
"    ], but may be used for RSI in status epilepticus when the patient manifests hemodynamic compromise. We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    not be used because of its stimulant effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Reactive airway disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hemodynamically stable patients with severe bronchospasm requiring intubation, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    be used for induction, because of their bronchodilatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/23,59\">",
"     23,59",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    are acceptable alternatives. In hypotensive patients, we prefer ketamine or etomidate. None of these agents causes histamine release, unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    , which is not recommended for this reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    for induction of the patient with significant cardiovascular disease requiring RSI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/17,18,20,90\">",
"     17,18,20,90",
"    </a>",
"    ]. The hemodynamic stability it provides and the absence of induced hypertension make it preferable to other sedatives. Patients with coronary artery disease or suspected aortic dissection should receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     micrograms/kg)",
"    </span>",
"    as a pretreatment agent to mitigate the catecholamine release associated with laryngoscopy and intubation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etomidate'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    for induction of the patient in shock requiring RSI. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etomidate'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Ketamine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    causes a sympathetic surge that may augment endogenous catecholamines but may also elevate intracranial pressure.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    has been scrutinized because of its transient suppression of endogenous cortisol. More research is required in this area before a firm recommendation can be made. These issues are discussed in detail above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Elevated intracranial pressure'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Adrenocortical suppression'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CONDITIONS PRECLUDING USE OF A PARALYTIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions may exist that preclude the use of a paralytic for intubation (ie, precludes rapid sequence intubation [RSI]). The clinician may then decide to use an appropriate sedative or combination of sedatives and topical anesthesia to facilitate laryngoscopy and assess the airway, while allowing the patient to maintain his respiratory drive. This approach, referred to as a \"sedated look\" or \"awake look,\" is used when the clinician suspects the airway will be difficult to intubate, and allows the practitioner to verify that laryngeal structures are visible, before committing to paralysis.",
"   </p>",
"   <p>",
"    The sedated look approach is distinct from the older practice of \"intubation with sedation alone\" or \"non-paralytic RSI,\" in which the patient receives a full induction dose of a sedative agent, but no neuromuscular blocking agent. The older practice is to be avoided, as it creates a vulnerable, compromised patient in whom intubating conditions are far from ideal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. In general, if the clinician anticipates a difficult intubation which may preclude successful RSI, an \"awake look\" or \"sedated look\" is advised. If the clinician does not anticipate a difficult airway, RSI with a full induction dose of a sedative agent, accompanied by a full dose of a paralytic agent, is advised.",
"   </p>",
"   <p>",
"    Multiple medications have been studied, primarily in the operating room, to determine which agents are appropriate for \"sedated looks\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/1,93-100\">",
"     1,93-100",
"    </a>",
"    ]. In general, the use of topical anesthesia (eg, nebulized 4 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) along with moderate sedation allows for a look into the airway, while enabling the patient to maintain respiratory drive and protective airway reflexes.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     Ketamine",
"    </a>",
"    is gaining popularity in this circumstance because it allows the patient to maintain respiratory drive while providing analgesia, amnesia, and sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/30/11754/abstract/56,62,66,94\">",
"     56,62,66,94",
"    </a>",
"    ]. Ketamine's analgesic properties allow it to be used as the sole agent in the bloody traumatized airway, when topical anesthesia is unlikely to work effectively. More research is needed to determine which sedatives are best for \"sedated looks\" in the emergent setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid sequence intubation (RSI) is the standard of care in emergency airway management for intubations not anticipated to be difficult. RSI involves combining a sedative and a paralytic agent to render a patient rapidly unconscious and flaccid in order to facilitate emergent tracheal intubation and to minimize the risk of aspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different clinical scenarios lend themselves to the use of certain sedatives when RSI is needed (",
"    <a class=\"graphic graphic_table graphicRef64272 \" href=\"UTD.htm?35/29/36316\">",
"     table 1",
"    </a>",
"    ). We suggest the following induction agents be used in the specific clinical circumstances described below (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with a head injury or potentially",
"      <strong>",
"       elevated intracranial pressure",
"      </strong>",
"      (ICP), adequate cerebral perfusion pressure must be maintained to prevent secondary brain injury. We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      for induction of these patients. For hypotensive patients, etomidate or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      may be used. Ketamine should be avoided in patients with hypertension or if elevated ICP is caused by spontaneous cerebral hemorrhage. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Head injury or stroke'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Etomidate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Ketamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the rapid sequence intubation (RSI) of patients in",
"      <strong>",
"       status epilepticus",
"      </strong>",
"      , we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"       thiopental",
"      </a>",
"      be used for induction. Reduced doses should be used in the unusual circumstance of seizure with hypotension.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       Etomidate",
"      </a>",
"      may be used when the patient manifests hemodynamic compromise. We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      &nbsp;",
"      <strong>",
"       NOT",
"      </strong>",
"      be used because of its stimulant effects. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Status epilepticus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the",
"      <strong>",
"       hemodynamically stable",
"      </strong>",
"      patient with",
"      <strong>",
"       severe bronchospasm",
"      </strong>",
"      requiring intubation, we suggest induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       Etomidate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      is an acceptable alternative. In",
"      <strong>",
"       hemodynamically unstable",
"      </strong>",
"      patients with severe bronchospasm, we suggest ketamine or etomidate. We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"       thiopental",
"      </a>",
"      &nbsp;",
"      <strong>",
"       NOT",
"      </strong>",
"      be used in these patients because it provokes histamine release and can induce or exacerbate bronchospasm. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Reactive airway disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For induction of the patient with",
"      <strong>",
"       cardiovascular compromise",
"      </strong>",
"      requiring RSI, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      because of the hemodynamic stability it provides. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cardiovascular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Etomidate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For induction of the patient in",
"      <strong>",
"       shock",
"      </strong>",
"      requiring RSI, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      . If etomidate is used in a patient with sepsis and hypotension refractory to treatment with fluid resuscitation and a vasopressor, we suggest that a single dose of glucocorticoid (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      100 mg IV) be given. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Shock'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Etomidate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Ketamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For induction of most patients with conditions precluding the use of paralytics in whom an \"awake look\" is necessary for intubation, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      . Ketamine may not be appropriate when these patients have cardiovascular disease or hypertension. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Conditions precluding use of a paralytic'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Ketamine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/1\">",
"      Li J, Murphy-Lavoie H, Bugas C, et al. Complications of emergency intubation with and without paralysis. Am J Emerg Med 1999; 17:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/2\">",
"      Sagarin MJ, Chiang V, Sakles JC, et al. Rapid sequence intubation for pediatric emergency airway management. Pediatr Emerg Care 2002; 18:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/3\">",
"      Sakles JC, Laurin EG, Rantapaa AA, Panacek EA. Airway management in the emergency department: a one-year study of 610 tracheal intubations. Ann Emerg Med 1998; 31:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/4\">",
"      Tayal VS, Riggs RW, Marx JA, et al. Rapid-sequence intubation at an emergency medicine residency: success rate and adverse events during a two-year period. Acad Emerg Med 1999; 6:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/5\">",
"      Sivilotti ML, Filbin MR, Murray HE, et al. Does the sedative agent facilitate emergency rapid sequence intubation? Acad Emerg Med 2003; 10:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/6\">",
"      Ballard N, Robley L, Barrett D, et al. Patients' recollections of therapeutic paralysis in the intensive care unit. Am J Crit Care 2006; 15:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/7\">",
"      Playfor SD, Thomas DA, Choonara I I. Recall following paediatric intensive care. Paediatr Anaesth 2000; 10:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/8\">",
"      Topulos GP, Lansing RW, Banzett RB. The experience of complete neuromuscular blockade in awake humans. J Clin Anesth 1993; 5:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/9\">",
"      Wagner BK, Zavotsky KE, Sweeney JB, et al. Patient recall of therapeutic paralysis in a surgical critical care unit. Pharmacotherapy 1998; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/10\">",
"      Sivilotti ML, Ducharme J. Randomized, double-blind study on sedatives and hemodynamics during rapid-sequence intubation in the emergency department: The SHRED Study. Ann Emerg Med 1998; 31:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/11\">",
"      Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. J Emerg Med 2006; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/12\">",
"      El-Orbany MI, Wafai Y, Joseph NJ, Salem MR. Does the choice of intravenous induction drug affect intubation conditions after a fast-onset neuromuscular blocker? J Clin Anesth 2003; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/13\">",
"      Skinner HJ, Biswas A, Mahajan RP. Evaluation of intubating conditions with rocuronium and either propofol or etomidate for rapid sequence induction. Anaesthesia 1998; 53:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/14\">",
"      Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997; 15:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/15\">",
"      Benson M, Junger A, Fuchs C, et al. Use of an anesthesia information management system (AIMS) to evaluate the physiologic effects of hypnotic agents used to induce anesthesia. J Clin Monit Comput 2000; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/16\">",
"      Fuchs-Buder T, Sparr HJ, Ziegenfuss T. Thiopental or etomidate for rapid sequence induction with rocuronium. Br J Anaesth 1998; 80:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/17\">",
"      Guldner G, Schultz J, Sexton P, et al. Etomidate for rapid-sequence intubation in young children: hemodynamic effects and adverse events. Acad Emerg Med 2003; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/18\">",
"      Jellish WS, Riche H, Salord F, et al. Etomidate and thiopental-based anesthetic induction: comparisons between different titrated levels of electrophysiologic cortical depression and response to laryngoscopy. J Clin Anesth 1997; 9:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/19\">",
"      Sokolove PE, Price DD, Okada P. The safety of etomidate for emergency rapid sequence intubation of pediatric patients. Pediatr Emerg Care 2000; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/20\">",
"      Zed PJ, Abu-Laban RB, Harrison DW. Intubating conditions and hemodynamic effects of etomidate for rapid sequence intubation in the emergency department: an observational cohort study. Acad Emerg Med 2006; 13:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/21\">",
"      Oglesby AJ. Should etomidate be the induction agent of choice for rapid sequence intubation in the emergency department? Emerg Med J 2004; 21:655.",
"     </a>",
"    </li>",
"    <li>",
"     Schneider, RE, Caro, DA. Pretreatment agents. In: Manual of Emergency Airway Management, Walls, RM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/23\">",
"      Eames WO, Rooke GA, Wu RS, Bishop MJ. Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation. Anesthesiology 1996; 84:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/24\">",
"      Kox WJ, von Heymann C, Heinze J, et al. Electroencephalographic mapping during routine clinical practice: cortical arousal during tracheal intubation? Anesth Analg 2006; 102:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/25\">",
"      Reddy RV, Moorthy SS, Dierdorf SF, et al. Excitatory effects and electroencephalographic correlation of etomidate, thiopental, methohexital, and propofol. Anesth Analg 1993; 77:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/26\">",
"      Cohan P, Wang C, McArthur DL, et al. Acute secondary adrenal insufficiency after traumatic brain injury: a prospective study. Crit Care Med 2005; 33:2358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/27\">",
"      den Brinker M, Joosten KF, Liem O, et al. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005; 90:5110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/28\">",
"      Jackson WL Jr. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: a critical appraisal. Chest 2005; 127:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/29\">",
"      Schenarts CL, Burton JH, Riker RR. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 2001; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/30\">",
"      Malerba G, Romano-Girard F, Cravoisy A, et al. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005; 31:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/31\">",
"      Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/32\">",
"      Hohl CM, Kelly-Smith CH, Yeung TC, et al. The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: a systematic review. Ann Emerg Med 2010; 56:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/33\">",
"      Chan CM, Mitchell AL, Shorr AF. Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med 2012; 40:2945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/34\">",
"      Tekwani KL, Watts HF, Rzechula KH, et al. A prospective observational study of the effect of etomidate on septic patient mortality and length of stay. Acad Emerg Med 2009; 16:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/35\">",
"      Cuthbertson BH, Sprung CL, Annane D, et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009; 35:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/36\">",
"      Dmello D, Taylor S, O'Brien J, Matuschak GM. Outcomes of etomidate in severe sepsis and septic shock. Chest 2010; 138:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/37\">",
"      McPhee LC, Badawi O, Fraser GL, et al. Single-dose etomidate is not associated with increased mortality in ICU patients with sepsis: analysis of a large electronic ICU database. Crit Care Med 2013; 41:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/38\">",
"      Payen JF, Dupuis C, Trouve-Buisson T, et al. Corticosteroid after etomidate in critically ill patients: a randomized controlled trial. Crit Care Med 2012; 40:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/39\">",
"      Blumer JL. Clinical pharmacology of midazolam in infants and children. Clin Pharmacokinet 1998; 35:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/40\">",
"      Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997; 15:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/41\">",
"      Sagarin MJ, Barton ED, Sakles JC, et al. Underdosing of midazolam in emergency endotracheal intubation. Acad Emerg Med 2003; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/42\">",
"      de Wildt SN, de Hoog M, Vinks AA, et al. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med 2003; 31:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/43\">",
"      Tobias JD, Berkenbosch JW. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J 2004; 97:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/44\">",
"      Mulla H, McCormack P, Lawson G, et al. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology 2003; 99:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/45\">",
"      Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest 2005; 128:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/46\">",
"      Russo H, Bressolle F. Pharmacodynamics and pharmacokinetics of thiopental. Clin Pharmacokinet 1998; 35:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/47\">",
"      Reich DL, Hossain S, Krol M, et al. Predictors of hypotension after induction of general anesthesia. Anesth Analg 2005; 101:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/48\">",
"      Hirota K, Ohtomo N, Hashimoto Y, et al. Effects of thiopental on airway calibre in dogs: direct visualization method using a superfine fibreoptic bronchoscope. Br J Anaesth 1998; 81:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/49\">",
"      Keel M, Mica L, Stover J, et al. Thiopental-induced apoptosis in lymphocytes is independent of CD95 activation. Anesthesiology 2005; 103:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/50\">",
"      Ploppa A, Kiefer RT, Noh&eacute; B, et al. Dose-dependent influence of barbiturates but not of propofol on human leukocyte phagocytosis of viable Staphylococcus aureus. Crit Care Med 2006; 34:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/51\">",
"      Sato M, Tanaka S, Suzuki K, et al. Complications associated with barbiturate therapy. Resuscitation 1989; 17:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/52\">",
"      Schal&eacute;n W, Messeter K, Nordstr&ouml;m CH. Complications and side effects during thiopentone therapy in patients with severe head injuries. Acta Anaesthesiol Scand 1992; 36:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/53\">",
"      Stover JF, Stocker R. Barbiturate coma may promote reversible bone marrow suppression in patients with severe isolated traumatic brain injury. Eur J Clin Pharmacol 1998; 54:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/54\">",
"      Loop T, Humar M, Pischke S, et al. Thiopental inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappaB through suppression of kappaB kinase activity. Anesthesiology 2003; 99:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/55\">",
"      L&aring;ngsj&ouml; JW, Kaisti KK, Aalto S, et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003; 99:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/56\">",
"      Rogers R, Wise RG, Painter DJ, et al. An investigation to dissociate the analgesic and anesthetic properties of ketamine using functional magnetic resonance imaging. Anesthesiology 2004; 100:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/57\">",
"      Hanouz JL, Persehaye E, Zhu L, et al. The inotropic and lusitropic effects of ketamine in isolated human atrial myocardium: the effect of adrenoceptor blockade. Anesth Analg 2004; 99:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/58\">",
"      Hanouz JL, Zhu L, Persehaye E, et al. Ketamine preconditions isolated human right atrial myocardium: roles of adenosine triphosphate-sensitive potassium channels and adrenoceptors. Anesthesiology 2005; 102:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/59\">",
"      Allen JY, Macias CG. The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma. Ann Emerg Med 2005; 46:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/60\">",
"      Chen RM, Chen TL, Lin YL, et al. Ketamine reduces nitric oxide biosynthesis in human umbilical vein endothelial cells by down-regulating endothelial nitric oxide synthase expression and intracellular calcium levels. Crit Care Med 2005; 33:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/61\">",
"      Ho KK, Flood P. Single amino acid residue in the extracellular portion of transmembrane segment 2 in the nicotinic alpha7 acetylcholine receptor modulates sensitivity to ketamine. Anesthesiology 2004; 100:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/62\">",
"      Berkenbosch JW, Graff GR, Stark JM. Safety and efficacy of ketamine sedation for infant flexible fiberoptic bronchoscopy. Chest 2004; 125:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/63\">",
"      Grace RF. The effect of variable-dose diazepam on dreaming and emergence phenomena in 400 cases of ketamine-fentanyl anaesthesia. Anaesthesia 2003; 58:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/64\">",
"      Wyte SR, Shapiro HM, Turner P, Harris AB. Ketamine-induced intracranial hypertension. Anesthesiology 1972; 36:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/65\">",
"      Gardner AE, Dannemiller FJ, Dean D. Intracranial cerebrospinal fluid pressure in man during ketamine anesthesia. Anesth Analg 1972; 51:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/66\">",
"      Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury? Anesth Analg 2005; 101:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/67\">",
"      Alban&egrave;se J, Arnaud S, Rey M, et al. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. Anesthesiology 1997; 87:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/68\">",
"      Bourgoin A, Alban&egrave;se J, L&eacute;one M, et al. Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. Crit Care Med 2005; 33:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/69\">",
"      Schmittner MD, Vajkoczy SL, Horn P, et al. Effects of fentanyl and S(+)-ketamine on cerebral hemodynamics, gastrointestinal motility, and need of vasopressors in patients with intracranial pathologies: a pilot study. J Neurosurg Anesthesiol 2007; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/70\">",
"      L&aring;ngsj&ouml; JW, Salmi E, Kaisti KK, et al. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 2004; 100:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/71\">",
"      Veselis RA, Reinsel RA, Feshchenko VA, Johnson R Jr. Information loss over time defines the memory defect of propofol: a comparative response with thiopental and dexmedetomidine. Anesthesiology 2004; 101:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/72\">",
"      Veselis RA, Feshchenko VA, Reinsel RA, et al. Propofol and thiopental do not interfere with regional cerebral blood flow response at sedative concentrations. Anesthesiology 2005; 102:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/73\">",
"      Kodaka M, Johansen JW, Sebel PS. The influence of gender on loss of consciousness with sevoflurane or propofol. Anesth Analg 2005; 101:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/74\">",
"      Shangguan WN, Lian Q, Aarons L, et al. Pharmacokinetics of a single bolus of propofol in chinese children of different ages. Anesthesiology 2006; 104:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/75\">",
"      Mu&ntilde;oz HR, Cort&iacute;nez LI, Ibacache ME, Altermatt FR. Estimation of the plasma effect site equilibration rate constant (ke0) of propofol in children using the time to peak effect: comparison with adults. Anesthesiology 2004; 101:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/76\">",
"      Conti G, Ferretti A, Tellan G, et al. Propofol induces bronchodilation in a patient mechanically ventilated for status asthmaticus. Intensive Care Med 1993; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/77\">",
"      Pizov R, Brown RH, Weiss YS, et al. Wheezing during induction of general anesthesia in patients with and without asthma. A randomized, blinded trial. Anesthesiology 1995; 82:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/78\">",
"      Bein B, Renner J, Caliebe D, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005; 100:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/79\">",
"      Ebert TJ. Sympathetic and hemodynamic effects of moderate and deep sedation with propofol in humans. Anesthesiology 2005; 103:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/80\">",
"      Masuda T, Tomiyama Y, Kitahata H, et al. Propofol inhibits volume-sensitive chloride channels in human coronary artery smooth muscle cells. Anesth Analg 2003; 97:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/81\">",
"      Win NN, Fukayama H, Kohase H, Umino M. The different effects of intravenous propofol and midazolam sedation on hemodynamic and heart rate variability. Anesth Analg 2005; 101:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/82\">",
"      Steiner LA, Johnston AJ, Chatfield DA, et al. The effects of large-dose propofol on cerebrovascular pressure autoregulation in head-injured patients. Anesth Analg 2003; 97:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/83\">",
"      Aitkenhead AR, Pepperman ML, Willatts SM, et al. Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 1989; 2:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/84\">",
"      Whyte SD, Booker PD, Buckley DG. The effects of propofol and sevoflurane on the QT interval and transmural dispersion of repolarization in children. Anesth Analg 2005; 100:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/85\">",
"      Paventi S, Santevecchi A, Ranieri R. Effects of sevoflurane versus propofol on QT interval. Minerva Anestesiol 2001; 67:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/86\">",
"      Gottschling S, Meyer S, Krenn T, et al. Effects of short-term propofol administration on pancreatic enzymes and triglyceride levels in children. Anaesthesia 2005; 60:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/87\">",
"      Marvez-Valls E, Houry D, Ernst AA, et al. Protocol for rapid sequence intubation in pediatric patients -- a four-year study. Med Sci Monit 2002; 8:CR229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/88\">",
"      Sonday CJ, Axelband J, Jacoby J, et al. Thiopental vs. etomidate for rapid sequence intubation in aeromedicine. Prehosp Disaster Med 2005; 20:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/89\">",
"      Choi YF, Wong TW, Lau CC. Midazolam is more likely to cause hypotension than etomidate in emergency department rapid sequence intubation. Emerg Med J 2004; 21:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/90\">",
"      Sarkar M, Laussen PC, Zurakowski D, et al. Hemodynamic responses to etomidate on induction of anesthesia in pediatric patients. Anesth Analg 2005; 101:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/91\">",
"      Kirkegaard-Nielsen H, Caldwell JE, Berry PD. Rapid tracheal intubation with rocuronium: a probability approach to determining dose. Anesthesiology 1999; 91:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/92\">",
"      Naguib M, Samarkandi A, Riad W, Alharby SW. Optimal dose of succinylcholine revisited. Anesthesiology 2003; 99:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/93\">",
"      Durmus M, Ender G, Kadir BA, et al. Remifentanil with thiopental for tracheal intubation without muscle relaxants. Anesth Analg 2003; 96:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/94\">",
"      Bahk JH, Sung J, Jang IJ. A comparison of ketamine and lidocaine spray with propofol for the insertion of laryngeal mask airway in children: a double-blinded randomized trial. Anesth Analg 2002; 95:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/95\">",
"      Bair AE, Filbin MR, Kulkarni RG, Walls RM. The failed intubation attempt in the emergency department: analysis of prevalence, rescue techniques, and personnel. J Emerg Med 2002; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/96\">",
"      Bozeman WP, Young S. Etomidate as a sole agent for endotracheal intubation in the prehospital air medical setting. Air Med J 2002; 21:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/97\">",
"      De F&aacute;tima De Assun&ccedil;&atilde;o Braga A, Da Silva Braga FS, Pot&eacute;rio GM, et al. The effect of different doses of propofol on tracheal intubating conditions without muscle relaxant in children. Eur J Anaesthesiol 2001; 18:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/98\">",
"      Erhan E, Ugur G, Alper I, et al. Tracheal intubation without muscle relaxants: remifentanil or alfentanil in combination with propofol. Eur J Anaesthesiol 2003; 20:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/99\">",
"      Liou CM, Hung WT, Chen CC, et al. Improving the success rate of laryngeal mask airway insertion during etomidate induction by using fentanyl or succinylcholine. Acta Anaesthesiol Taiwan 2004; 42:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/30/11754/abstract/100\">",
"      Taha S, Siddik-Sayyid S, Alameddine M, et al. Propofol is superior to thiopental for intubation without muscle relaxants. Can J Anaesth 2005; 52:249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 271 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-189.41.172.26-EAC8C0E9A4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11754=[""].join("\n");
var outline_f11_30_11754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RAPID SEQUENCE INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDUCTION AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Etomidate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - General use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adrenocortical suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ketamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - General use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Elevated intracranial pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Propofol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHOICE OF INDUCTION AGENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Head injury or stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Status epilepticus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Reactive airway disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CONDITIONS PRECLUDING USE OF A PARALYTIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/271\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/271|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 1\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/271|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/29/36316\" title=\"table 1\">",
"      Rapid sequence intubation induction agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=related_link\">",
"      Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=related_link\">",
"      Pretreatment agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_30_11755="Complications of central venous catheterization";
var content_f11_30_11755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of central venous catheterization",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Air embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic duct injury (with left SC or left IJ approach)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catheter malposition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumothorax or hemothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Delayed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venous thrombosis, pulmonary emboli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catheter migration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catheter embolization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial perforation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nerve injury",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11755=[""].join("\n");
var outline_f11_30_11755=null;
var title_f11_30_11756="Interpretation of sweat chloride";
var content_f11_30_11756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F88515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F88515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpretation of sweat chloride test results for diagnosis of cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sweat chloride concentration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Result",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Newborn to 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &le;29 mmol/L",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        CF very unlikely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        30 to 59 mmol/L",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Possible CF, additional testing recommended*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;60 mmol/L",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        Diagnosis of CF, if confirmed by a second test and if clinical symptoms consistent with CF are present",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Infants &ge;6 months, children and adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &le;39 mmol/L",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        CF very unlikely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        40 to 59 mmol/L",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Possible CF, additional testing recommended*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;60 mmol/L",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        Diagnosis of CF, if confirmed by a second test and if clinical symptoms consistent with CF are present",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CF: cystic fibrosis.",
"     <br/>",
"     * Additional testing usually consists of molecular diagnosis (DNA analysis) and a second sweat test.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Clinical symptoms of CF are not required among newborns identified through a screening program, or among siblings of patients with CF who are diagnosed by shared genotype.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153:S4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11756=[""].join("\n");
var outline_f11_30_11756=null;
var title_f11_30_11757="Histolog classification STS II";
var content_f11_30_11757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic classification of soft tissue sarcomas - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of blood and lymph vessels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemangioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epithelioid hemangioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphangioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate (locally aggressive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kaposiform hemangioendothelioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate (rarely metastasizing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemangioendothelioma, retiform and composite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papillary intralymphatic angioendothelioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kaposis sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epithelioid hemangioendothelioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fibroblastic and myofibroblastic tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nodular fasciitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proliferative fasciitis, proliferative myositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myositis ossificans (fibro-osseous pseudotumor of the digits)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elastofibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Juvenile hyaline fibromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inclusion body fibromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fibroma of tendon sheath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desmoplastic fibroblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mammary-type myofibroblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiomy of fibroblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gardner fibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcifying fibrous tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giant cell angiofibroma, Cellular angiofibroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate (locally aggressive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Superficial fibromatoses (palmar, plantar)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desmoid-type fibromatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipofibromatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate (rarely metastasizing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Solitary fibrous tumor, with or without hemangiopericytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory myofibroblastic tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low-grade myofibroblastic sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myxoinflammatory fibroblastic sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infantile fibrosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adult fibrosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myxofibrosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low-grade fibromyxoid sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sclerosing epthelioid fibrosarcoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Fletcher CDM, Unni KK, Mertens F, Eds. Pathology and Genetics of tumours of soft tissue and bone. Lyon, France, IARC 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11757=[""].join("\n");
var outline_f11_30_11757=null;
var title_f11_30_11758="US trends in childhood obesity";
var content_f11_30_11758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Prevalence of obesity among children and adolescents, by age group -- United States, 1963-2008",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the United States Health and Nutrition Examination Surveys (NHANES).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. CDC Grand Rounds: Childhood obesity in the United States. MMWR Morb Mortal Wkly Rep 2011; 60:42.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11758=[""].join("\n");
var outline_f11_30_11758=null;
var title_f11_30_11759="Airflow limitation curves";
var content_f11_30_11759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common patterns on flow-volume loops",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The flow-volume loops are plotted again absolute lung volume to show the influence of changes in lung volume. Upper left panel: Patient with airflow limitation (solid lines) compared to predicted (dashed lines). Upper middle panel: Patient with mixed disease with reduced airflow and reduced lung volumes. It is important to note that if one only measures airflow, this mixed picture would have been missed. Upper right panel: The flow volume loop observed in a patient with restrictive disease where the increased recoil causes increased airflow. Bottom left panel: Consistent truncation of the inspiratory phase of the loop, characteristic of a variable extrathoracic obstruction, eg, tracheal collapse as might be due to intubation trauma. Bottom middle panel: Another extrathoracic process of a more transient nature characteristic of vocal cord dysfunction. Bottom right panel: Consistent truncation of both inspiration and expiration, characteristic of a fixed obstruction, eg, tracheal stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_30_11759=[""].join("\n");
var outline_f11_30_11759=null;
